Is Rani Therapeutics Holdings, Inc. (RANI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 18.6% / 30% | 17.3% / 30% | 0.3% / 30% | 171.5% / 5% | ✗ NOT HALAL |
| DJIM | 18.6% / 33% | 17.3% / 33% | 0.3% / 33% | 171.5% / 5% | ✗ NOT HALAL |
| MSCI | 81.1% / 33% | 75.4% / 33% | 1.2% / 33% | 171.5% / 5% | ✗ NOT HALAL |
| S&P | 18.6% / 33% | 17.3% / 33% | 0.3% / 33% | 171.5% / 5% | ✗ NOT HALAL |
| FTSE | 81.1% / 33% | 75.4% / 33% | 1.2% / 50% | 171.5% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -584.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -182.0% | |
| Return on Assets (ROA) | -50.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$35M |
| Free Cash Flow | -$36M |
| Total Debt | $30M |
| Debt-to-Equity | 10.4 |
| Current Ratio | 4.2 |
| Total Assets | $37M |
Price & Trading
| Last Close | $1.08 |
| 50-Day MA | $1.28 |
| 200-Day MA | $1.07 |
| Avg Volume | 1.1M |
|
52-Week Range
$0.39
| |
About Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Rani Therapeutics Holdings, Inc. (RANI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Rani Therapeutics Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Rani Therapeutics Holdings, Inc.'s debt ratio?
Rani Therapeutics Holdings, Inc.'s debt ratio is 18.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 81.1%.
What are Rani Therapeutics Holdings, Inc.'s key financial metrics?
Rani Therapeutics Holdings, Inc. has a market capitalization of $81M, and revenue of $1M. Return on equity stands at -182.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.